CG
HAE icon

Carmignac Gestion’s Haemonetics HAE Stock Holding History

Carmignac Gestion’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-440,139
Closed -$48.9M – 139
2021
Q1 		$48.9M Buy
440,139
+134,592
+44% +$16.7M 0.56% 45
2020
Q4 		$36.3M Buy
+305,547
New +$32.9M 0.38% 50

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
LCOV
London Company of Virginia Richmond, Virginia $16.2B AUM 17.5% 1-Year Est. Return
LCP
LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Carmignac Gestion's HAE Position: Q2 2021 in Review

Carmignac Gestion sold out of Haemonetics (HAE) in Q2 2021, closing a stake of 440,139 shares — an estimated $48.9M sold.

Carmignac Gestion first reported a position in HAE in Q4 2020 and held it in 2 quarters. The position peaked at $48.9M in Q1 2021. 258 funds tracked by Wall St. Rank hold HAE as of Q2 2021.

  • Carmignac Gestion reported no remaining Haemonetics position as of Q2 2021 after selling out during the quarter.
  • Carmignac Gestion sold 440,139 Haemonetics shares in Q2 2021, an estimated $48.9M.
  • Carmignac Gestion first reported a position in Haemonetics in Q4 2020 and held it in 2 quarters.
  • Carmignac Gestion's Haemonetics position peaked at $48.9M in Q1 2021.
  • 258 funds tracked by Wall St. Rank held Haemonetics as of Q2 2021.

Based on Carmignac Gestion's 13F filing for Q2 2021, filed 13 Aug 2021.